AUPH - CIK 0001600620
The table below shows Aurinia Pharmaceuticals Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | $32.56M | $1.30M | -$18.60M | -$31.67M | -$46.75M | -$53.54M |
| Capital expenditure | - | - | - | - | - | - |
| Investing cash flow | -$18.08M | $31.03M | $49.23M | $24.86M | -$53.02M | -$67.25M |
| Dividends paid | - | - | - | - | - |
Aurinia Pharmaceuticals Inc. reported operating cash flow of $135.66M for fiscal year 2025. That is up 205.6% from $44.39M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow grew from -$51.61M (FY 2018) to $135.66M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | $36.16M | $46.92M | $12.30M | $0.00 | - | - |
| Financing cash flow | -$53.69M | -$49.34M | -$15.05M | $1.64M | $405.00K | $5.03M |